Noopept ntsiav tshuaj, lub npe tshuaj yog N-phenylacetyl-L-prolyl glycine ethyl ester, uas yog cyclic glycine proline dipeptide derivative tsim nyob rau hauv Russia. Cov tshuaj no txhawb nqa nws cov bioavailability thiab ntshav- lub hlwb thaiv kev muaj peev xwm los ntawm kev hloov kho nrog phenylacetyl thiab ethyl ester functional pawg. Cov kev sim tsiaj tau pom tias qhov siab tshaj plaws concentration (1.289 μ g / mL) hauv cov ntaub so ntswg hlwb tuaj yeem ncav cuag li ntawm 7 feeb tom qab kev tswj hwm qhov ncauj ntawm 8mg / kg koob tshuaj, thiab tsis muaj qhov sib txawv tseem ceeb hauv cov ntshav thiab cov paj hlwb concentration, lees paub nws cov txiaj ntsig transmembrane.
Lub capsule txais cov cuab yeej siv microcrystalline cellulose los xyuas kom meej cov tshuaj ruaj khov tso rau hauv txoj hnyuv. Lub qhov ncauj bioavailability nce mus txog 89%, deb tshaj qhov 1-2% ntawm piracetam, ua tsaug rau kev zam ntawm nws cov ethyl ester pawg ntawm thawj qhov tshwm sim. Lub sijhawm siab tshaj plaws ntawm cov tshuaj ntshav siab (Tmax) yog 0.115 teev (7 feeb), Cmax yog 1.289 μ g / mL (8mg / kg koob), thiab qhov sib piv ntawm lub hlwb cov ntaub so ntswg rau cov ntshav concentration yog 1: 0.98, lees paub tias nws muaj peev xwm nkag mus rau lub hlwb zoo heev.
Peb cov khoom
Cov ntaub ntawv ntxiv ntawm chemical compound:
| Khoom npe | Noopept hmoov | Noopept ntsiav tshuaj | Noopept Capsules |
| Yam khoom | Hmoov | Tablet | Capsules |
| Khoom Purity | Ntau dua lossis sib npaug li 99% | Ntau dua lossis sib npaug li 99% | Ntau dua lossis sib npaug li 99% |
| Khoom Specifications | Customizable | Customizable | Customizable |
| Pob khoom | Customizable | Customizable | Customizable |
Peb Cov Khoom
Noopept +. COA
 |
||
Certificate of Analysis |
||
|
Compound npe |
Noopept | |
|
CAS Nr. |
157115-85-0 | |
|
Qib |
Pharmaceutical qib | |
|
Ntau |
Customized | |
|
Ntim txheem |
Customized | |
| Chaw tsim tshuaj paus | Shaanxi BLOOM TECH Co., Ltd | |
|
Ntau No. |
20250109001 |
|
|
MFG |
Jan 12th 2025 |
|
|
EXP |
Jan 8th 2029 |
|
|
Qauv |
|
|
| TEST STANDARD | GB/T24768-2009 Kev lag luam. Stnndard | |
|
Yam khoom |
Enterprise txheem |
Kev txheeb xyuas qhov tshwm sim |
|
Qhov tshwm sim |
Dawb los yog yuav luag dawb hmoov |
Ua raws |
|
Cov ntsiab lus dej |
Tsawg dua lossis sib npaug li 4.5% |
0.30% |
| Poob rau ziab |
Tsawg dua lossis sib npaug li 1.0% |
0.15% |
|
Hnyav Hlau |
Pb Tsawg dua lossis sib npaug li 0.5ppm |
N.D. |
|
Tsawg dua lossis sib npaug li 0.5ppm |
N.D. | |
|
Hg Tsawg dua lossis sib npaug li 0.5ppm |
N.D. | |
|
Cd Tsawg dua lossis sib npaug li 0.5ppm |
N.D. | |
|
Purity (HPLC) |
Ntau dua lossis sib npaug li 99.0% |
99.5% |
|
Ib qho impurity |
<0.8% |
0.48% |
|
Residue ntawm ignition |
<0.20% |
0.064% |
|
Tag nrho microbial suav |
Tsawg dua lossis sib npaug li 750cfu / g |
80 |
|
E. Coli |
Tsawg dua lossis sib npaug li 2MPN / g |
N.D. |
|
Salmonella |
N.D. | N.D. |
|
Ethanol (los ntawm GC) |
Tsawg dua lossis sib npaug li 5000ppm |
400ppm ua |
|
Cia |
Khaws rau hauv qhov chaw kaw, tsaus thiab qhuav ntawm -20 degrees |
|
|
|
||
Pharmacokinetic yam ntxwv
Absorption thiab kev faib tawm:
Noopept ntsiav tshuajyog qhov ncauj bioavailability nce mus txog 89%, deb tshaj Piracetam (1-2%). Kev tswj hwm sublingual tuaj yeem hla dhau qhov kev cuam tshuam thawj zaug, tab sis yuav tsum ceev faj tiv thaiv qhov kev pheej hmoo ntawm cov ntshav siab poob qis - kev sim tsiaj tau pom tias 0.5mg / kg sublingual kev tswj hwm tuaj yeem txo qhov siab ntawm cov hlab ntsha los ntawm 22 ± 3mmHg rau li 45 feeb.
Metabolism thiab excretion:
Feem ntau metabolized los ntawm daim siab CYP3A4 enzyme, tsim L- isomer metabolites nrog kev tiv thaiv kev ntxhov siab. Ib nrab ntawm - lub neej yog 1.1-1.5 teev, thiab nws yuav tsum tau muab faib ua cov koob tshuaj txhua hnub kom tswj tau lub xeev khov kho.
Formulation sib txawv:
Muaj kev tsis sib haum xeeb txog qhov sib npaug ntawm cov lus Lavxias ntawm cov ntsiav tshuaj sublingual (10mg) thiab American version ntawm capsules (30mg). Raws li kev tshawb fawb 2023 Zhihu cov neeg siv, 62% ntawm cov neeg siv ntseeg tias cov ntsiav tshuaj sublingual siv tau sai dua (15-20 feeb vs. capsules 30-45 feeb), tab sis lub sijhawm ua haujlwm hauv pawg tshuaj ntsiav tau txuas ntxiv mus rau 6-8 teev.
Kev puas hlwb me me (MCI): Hauv ob - qhov muag tsis pom kev sim hauv 2025, 268 tus neeg mob tau cuv npe. Cov pab pawg sim (20mg / d) tau pom 3.8 taw qhia kev txhim kho hauv MMSE cov qhab nia (1.2 cov ntsiab lus hauv pawg placebo) thiab 4.1 taw tes txo qis hauv ADAS Cog cov qhab nia (p<0.01). Especially in the execution function sub item, the completion time of Trail Making Test-B in the experimental group was reduced by 28%.
Vascular dementia: Txoj kev tshawb fawb txog kev cuam tshuam 56 hnub tau pom tias pawg 20mg / d tau nce MoCA cov qhab nia los ntawm 2.7 cov ntsiab lus, ua kom luv luv ntawm cov xwm txheej tshwm sim- cuam tshuam txog P300 los ntawm 32ms, qhia txog kev txhim kho hauv cov ntaub ntawv ceev.
Kev raug mob ntawm lub hlwb: Ib qho qhib daim ntawv sim ntawm 17 tus neeg mob nrog post- kev puas siab puas ntsws kev puas siab puas ntsws pom tau tias tom qab noj tshuaj tas li rau 90 hnub, tag nrho cov qhab nia RBANS tau nce los ntawm 19.3 cov ntsiab lus (p=0.003), nrog rau qhov pom kev ua haujlwm ntawm qhov chaw uas qhia txog kev txhim kho tseem ceeb tshaj plaws (+24.6 cov ntsiab lus).
Custom Notebook Solutions
Cov chaw thov uas muaj xwm txheej ceev
Biohacking Practice: Tus kws ua lag luam Jeffrey Wu daim ntawv qhia txog kev sim tus kheej qhia tau hais tias tom qab siv tas li rau 30 hnub, xim saturation pom tau nce 37% (tsim los ntawm FM100 xim pom kev), thiab cov ntsiab lus ntawm kev paub txog qhov pib poob los ntawm 12dB (lub suab ntshiab lub suab kuaj).
Kev pabcuam kab mob neurodegenerative: Alzheimer's tus qauv kev sim nas tau pom tias kev kho mob ua ke nrog memantine tuaj yeem ncua hippocampal atrophy los ntawm 41% thiab txo Tau protein phosphorylation qib los ntawm 29%.
Comorbidity Management of Mental Disorders: Kev tshawb nrhiav randomized controlled trial (RCT) ntawm 53 cov neeg mob uas muaj vascular depression pom tau tias tom qab 8 lub lis piam ntawm kev kho mob nrog 20mg / d nrog SSRIs, qhov txo qis hauv HAMD-17 qhab nia nce los ntawm 5.2 cov ntsiab lus piv rau pawg monotherapy (p{5}}), thiab QT tsis muaj kev pheej hmoo ntau ntxiv.
Noopept ntsiav tshuajyog ib tug hluavtaws txawj ntse txhawb cov tshuaj los ntawm Russia. Nws daim ntawv capsule nkag mus rau tib neeg lub cev los ntawm kev tswj hwm qhov ncauj thiab txhim kho kev txawj ntse los ntawm ntau yam -cov txiaj ntsig sib koom ua ke. Nws cov txheej txheem ntawm kev ua haujlwm suav nrog plaub txoj hauv kev: neuroprotection, neurotransmitter kev tswj hwm, kev loj hlob zoo stimulation, thiab tiv thaiv antioxidant.
Noopept txhim khu kev ciaj sia thiab sib txawv muaj peev xwm ntawm neural qia hlwb los ntawm IL-6 mediated overexpression mechanism ntawm lub hlwb-derived neurotrophic factor (BDNF). Cov kev sim tsiaj tau pom tias tom qab kev tswj hwm, qhov concentration ntawm BDNF hauv hippocampus nce 2.1 npaug piv rau pawg tswj hwm. Cov nyhuv no ncaj qha ntsig txog qhov txo qis hauv IL-6 concentration - qhov txo qis hauv IL-6 qib hauv lub hlwb tuaj yeem txo qhov inhibition ntawm BDNF noob qhia thiab txhawb nqa neuronal synaptic plasticity. Piv txwv li, hauv cov qauv kev raug mob ntawm lub hlwb, cov pab pawg kho mob Noopept tau nce cov ciaj sia taus ntawm hippocampal neurons los ntawm 37% thiab ntev lub sijhawm nco txog lub sijhawm khaws cia rau 2.3 npaug ntawm pawg tswj hwm.
Nws cov nyhuv neuroprotective kuj tau tshwm sim hauv kev tswj hwm ntawm calcium raws. Raws li calcium channel antagonist, Noopept tuaj yeem thaiv glutamate induced overactivation ntawm NMDA receptors thiab txo cov neuronal apoptosis induced los ntawm calcium influx. Cov kev tshawb fawb ua ntej tau lees paub tias koob tshuaj 0.5mg / kg tuaj yeem txo thaj tsam ntawm excitotoxic raug mob los ntawm 41%, thiab cov txheej txheem no muaj feem cuam tshuam nrog kev tiv thaiv mob stroke.
Neurotransmitter system tswj: cholinergic thiab glutamatergic tshuav nyiaj li cas
Kev txhim kho cholinergic system:
Noopept txhim kho kev kawm thiab kev nco ua haujlwm los ntawm kev txhawb nqa acetylcholine tso tawm. Nws lub hom phiaj suav nrog cholinergic neurons hauv basal forebrain thiab M1 receptors hauv hippocampus. Cov kev sim tsiaj txhu tau pom tias tom qab kev tswj hwm, qhov tseeb ntawm kev paub txog cov khoom tshiab hauv cov nas tau nce los ntawm 28%, thiab cov txiaj ntsig tsis cuam tshuam rau acetylcholinesterase kev ua si inhibition, qhia ncaj qha rau kev ua haujlwm ntawm presynaptic membrane tso tawm mechanism.
Glutamic acid system tswj:
Tsis zoo li cov tshuaj glutamate receptor agonists, Noopept siv lub tswv yim "kev tswj tsis zoo": los ntawm kev sib tw ntawm NMDA receptor glycine binding site, nws txo qhov tshwm sim ntawm receptor qhib, yog li txo oxidative kev nyuaj siab los ntawm calcium overload. Electrophysiological cov ntaub ntawv qhia tau hais tias ib tug concentration ntawm 10nM yuav txo tau lub amplitude ntawm excitatory postsynaptic muaj peev xwm (EPSP) nyob rau hauv hippocampal pyramidal hlwb los ntawm 34%, tsis muaj kev cuam tshuam rau AMPA receptor-mediated basal conduction.
Noopept tuaj yeem ua rau tib lub sijhawm txhawb kev qhia txog kev loj hlob ntawm paj hlwb (NGF) thiab BDNF, tsim ib qho kev pov hwm neuroprotective. Hauv kev sim hauv vitro neurosphere kab lis kev cai, tom qab 72 teev ntawm kev kho mob nrog cov concentration ntawm 1 μ M:
NGF secretion nce 2.7 npaug
BDNF mRNA qhia upregulated los ntawm 4.1-fold
Kev loj hlob ntawm cov txheej txheem neural tau nce 58%
Qhov kev sib koom ua ke no tau raug lees paub hauv tus qauv vascular dementia: tom qab kev tswj hwm tas li rau 56 hnub, tus neeg mob cov ntshav BDNF qib tau nce los ntawm 18.3 ng / mL mus rau 25.7 ng / mL, thiab MMSE cov qhab nia tau txhim kho los ntawm 3.8 cov ntsiab lus (cov pab pawg placebo 1.2 cov ntsiab lus). Nws yog ib qho tsim nyog sau cia tias nws cov nyhuv stimulating muaj ib koob tshuaj - nyob ntawm qhov pib - kev loj hlob yam qhia tau zoo li saturate thaum nws tshaj 30mg / d.
Antioxidant tiv thaiv system: dynamic tshuav nyiaj li cas ntawm SOD / MDA
Noopept tsim ib qho kev tiv thaiv antioxidant los ntawm kev txhim kho cov haujlwm ntawm superoxide dismutase (SOD). Tus H ₂ O ₂ - induced neuronal puas qauv qhia:
10nM concentration nce SOD kev ua haujlwm los ntawm 2.3 npaug
Cov ntsiab lus ntawm lipid peroxidation khoom MDA txo los ntawm 67%
Cell ciaj sia taus nce los ntawm 58% mus rau 89%
Nws cov tshuaj tiv thaiv kab mob antioxidant muaj feem xyuam rau kev ua kom lub zog ntawm cov khoom siv nuclear E2 ntsig txog yam 2 (Nrf2) txoj hauv kev. Gene nti tsom xam pom tias cov noob caj ces ntawm Nrf2 (xws li HO-1 thiab GCLC) tau hloov kho 3-5 zaug tom qab kev tswj hwm, tsim cov nyhuv antioxidant. Cov yam ntxwv no ua rau nws ua tau zoo nyob rau hauv tus qauv ischemia-reperfusion raug mob - cerebral infarction ntim tau txo los ntawm 42%, thiab cov qhab nia ntawm cov paj hlwb raug txo los ntawm 51%.
Cov qauv siv thiab cov tswv yim optimization
Kev npaj khomob Standardized
Dose gradient:
Kev paub txog kev txawj ntse: 10-20mg / d, noj qhov ncauj hauv ob koob
Neuroprotection: 30mg / d, ua ke nrog vitamin E 400IU / d
Kev kho mob rov qab: 40mg / d (yuav tsum tau siv nyob rau hauv kev saib xyuas)
Lub sijhawm noj tshuaj: Nws raug nquahu kom siv sijhawm 12 lub lis piam ua ib qho kev kho mob, thiab tsis txhob noj tshuaj rau 2 lub lis piam ntawm txhua chav kawm txhawm rau tiv thaiv receptor desensitization. Lub sijhawm ntev - ua raws- kev tshawb fawb txog xyoo 2024 tau pom tias kev paub txog kev noj qab haus huv ntawm pab pawg tshuaj tsis tu ncua (tso tseg 2 lub lis piam tom qab 4 lub lis piam) zoo dua li ntawm pawg tshuaj txuas ntxiv (p=0.04).
Efficiency txhim kho txoj kev npaj ua ke
Kev txhim kho Cholinergic: Thaum siv ua ke nrog 300mg / d alpha GPC, nws tuaj yeem txhim kho qhov tseeb ntawm kev ua haujlwm nco txog 23% (piv rau 14% hauv pawg monotherapy).
Antioxidant synergy: Ua ke nrog 200mg / d coenzyme Q10, nws tuaj yeem txo cov ntshav MDA los ntawm 31% thiab nce SOD kev ua haujlwm los ntawm 19%.
Neuroplasticity Txhawb nqa: Thaum ua ke nrog Omega-3 fatty acids (EPA 1000mg + DHA 500mg), lub cev ntim ntawm seahorses tau nce 2.1% tom qab 6 lub hlis, zoo dua li cov pab pawg monotherapy (0.7%).
Kev ua lag luam qauv thiab kev tswj hwm dynamics
Ntiaj teb no Regulatory Classification
Russia: suav nrog raws li cov tshuaj noj hauv kev pov hwm kho mob rau kev paub txog kev kho mob tom qab lub hlwb raug mob.
Teb Chaws Asmeskas: Muab faib ua cov khoom tsis muaj kev tswj hwm raws li Tsoom Fwv Teb Chaws Khoom Noj, Tshuaj, thiab Tshuaj pleev ib ce, tab sis tsis tau pom zoo rau kev siv kho mob los ntawm FDA, cais raws li cov khoom "grey area".
EU: Qee lub tebchaws (xws li Poland thiab Bulgaria) tso cai muag cov khoom noj khoom haus, tab sis lawv yuav tsum tau sau nrog cov lus ceeb toom "tsis raug tshuaj xyuas los ntawm FDA".
Kev Tswj Xyuas Zoo
Cov kev cai huv huv: USP cov qauv xav tau yam tsawg kawg nkaus ntawm 98.5%, cov ntsiab lus hlau hnyav tsawg dua lossis sib npaug li 10ppm, thiab cov kuab tshuaj seem (chloroform, ethanol) raws li ICH cov lus qhia.
Kev ntsuas kev ruaj ntseg: Kev ntsuas nrawm (40℃/ 75% RH) pom tias cov ntsiab lus ntawm cov ntsiav tshuaj txo qis dua los yog sib npaug li 2.3% thiab cov tshuaj ntsiav txo qis dua los yog sib npaug li 3.1% hauv 12 lub hlis.
Bioequivalence: FDA xav kom Cmax piv ntawm cov ntsiav tshuaj sublingual rau hauv qhov ncauj formulations nyob rau hauv thaj tsam ntawm 80-125%, thiab AUC piv yuav tsum nyob rau hauv thaj tsam ntawm 85-115%.
Tus nqi kho mob ntawmNoopept ntsiav tshuajraws li lub cim tshiab ntawm kev paub txog kev txawj ntse tau ua tiav ua ntej, tab sis ntev - cov ntaub ntawv kev nyab xeeb tseem yuav tsum tau txhim kho. Nyob rau hauv lub era ntawm precision tshuaj, tsim kom muaj cov kev npaj tshuaj kho tus kheej raws li biomarkers yuav yog ib txoj hauv kev tseem ceeb rau kev rhuav tshem cov kev kho mob uas twb muaj lawm. Nyob rau hauv lub neej yav tom ntej, nrog kev sib sib zog nqus ntawm neuroscience mechanism kev tshawb fawb, cov tshuaj no yuav tsum tau ua lub luag haujlwm ntau dua hauv kev tiv thaiv cov kab mob neurodegenerative.
Cov lus nug nquag
Noopept yog dab tsi zoo rau?
+
-
Noopept yog ib qho muaj zog nootropic compound paub txog nws txoj kev txawj ntse - txhim kho cov khoom. Nrog nws cov qauv tshwj xeeb, nws tau lees paub los txhawb kev nco, kev kawm, thiab tag nrho lub hlwb kom meej meej.
Noopept cuam tshuam rau lub hlwb li cas?
+
-
Los ntawm kev ua li ntawd, Noopept tuaj yeem txhawb nqa synaptic plasticity, txhawb kev tsim cov kev sib txuas tshiab ntawm cov neurons thiab txhim kho kev sib kis ntawm synaptic. Cov cuab yeej no ntseeg tau hais tias nws lub peev xwm los txhim kho kev kawm, kev sib koom ua ke ntawm kev nco, thiab kev paub yooj yim.
Puas yog Noopept ua rau koj tsaug zog?
+
-
Cov kev phiv tshwm sim ntawm noopept suav nrog kev pw tsaug zog (5/31 cov neeg mob), chim siab (3/31), thiab ntshav siab (7/31) (Neznamov thiab Teleshova, 2009). Mechanisms ntawm kev txiav txim los ntawm kev tshawb fawb preclinical Ib txoj kev tshawb fawb nyob rau hauv nas qhia tias noopept hla cov ntshav hlwb barrier.
Noopept puas pab nrog kev ntxhov siab?
+
-
Noopept, txawm li cas los xij, ua rau muaj cov nyhuv nootropic ntawm qhov qis dua thiab tuaj yeem siv rau ntau yam kab mob pathological; Piv txwv li, nws kuj qhia txog cov teebmeem anxiolytic thiab siv hauv kev kho kev ntxhov siab.
Cim npe nrov: Noopept capsules, lwm tus neeg, manufacturers, hoobkas, lag luam wholesale, yuav, nqe, tej, kev muag khoom